References
- Zuvich RL, McCauley JL, Pericak-Vance MA, et al. Genetics and pathogenesis of multiple sclerosis. Semin Immunol 2009;21:328-33
- Multiple Sclerosis Trust [Internet]. Understanding MS. Hertfordshire, UK. MST; 2017. Available at: https://www.mstrust.org.uk/
- Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006;7(Suppl2):S96-S104
- Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler 2012;18:7-15
- Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 2017;23:1123-36
- Multiple Sclerosis Society [Internet]. London, UK: MSS. 2017. Available at: https://www.mssociety.org.uk/
- Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol 2015;15:273-9
- European Medicines Agency [Internet]. GILENYA (Fingolimod) Summary of Product Characteristics. EMA; 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf
- European Medicines Agency [Internet]. TYSABRI (Natalizumab) Summary of Product Characteristics. London, UK. London, UK. EMA; 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf
- European Medicines Agency [Internet]. LEMTRADA (Alemtuzumab) Summary of Product Characteristics. London, UK. EMA; 2016. Available at: https://www.medicines.org.uk/emc/medicine/28917
- National Institute for Health and Care Excellence [Internet]. TA312 - Alemtuzumab for treating relapsing-remitting multiple sclerosis. London, UK. NICE; 2014. Available at: https://www.nice.org.uk/guidance/ta312
- National Institute for Health and Care Excellence [Internet]. TA127 - Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. London, UK. NICE; 2007. Available at: https://www.nice.org.uk/guidance/ta127
- Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015;86:208-15
- Willis MD, Harding KE, Pickersgill TP, et al. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Mult Scler 2016;22:1215-23
- European Medicines Agency [Internet]. MAVENCLAD (Cladribine) Summary of Product Characteristics. London, UK. EMA; 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004230/WC500234561.pdf
- Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26
- European Medicines Agency [Internet]. Mavenclad: EPAR Summary for the Public. London, UK. EMA; 2017. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004230/human_med_002150.jsp&mid=WC0b01ac058001d124
- Giovannoni G, Comi G, Cook S, et al. Clinical efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week phase IIIb extension trial to the CLARITY study (P3.028). Neurology 2016;86 (16 Supplement)
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. England, UK NICE; 2013. Available at: https://www.nice.org.uk/process/pmg9/chapter/foreword
- Siddiqui MK, Khurana IS, Budhia S, et al. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Curr Med Res Opin 2017:1-11. doi: 10.1080/03007995.2017.1407303
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
- Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open 2014;4(1):e004073
- Palace J, Duddy M, Bregenzer T, et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol 2015;14:497-505
- Tappenden P, Chilcott J, O’Hagan T, et al. [Internet]. Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis: Final report to the National Institute for Clinical Excellence. Sheffield, UK. NICE; 2001. Available at: http://www.academia.edu/8908699/Cost_effectiveness_of_beta_interferons_and_glatiramer_acetate_in_the_management_of_multiple_sclerosis.
- Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 2009;12:657-65
- Peninsula Technology Assessment Group (PenTAG) [Internet]. The effectiveness and cost-effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen. Southampton, UK. PenTAG; 2007. Available at: https://www.nice.org.uk/guidance/ta127/resources/multiple-sclerosis-natalizumab-evaluation-report-evidence-review-group-report2
- Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. PharmacoEconomics 2008;26:617-27
- Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522
- Gani R, Nixon RM, Hughes S, et al. Estimating the rates of disability progression in people with active relapsing-remitting multiple sclerosis. J Med Econ 2007;10:79-89
- Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology 2010;74:2004-15
- Department of Health [Internet]. National Health Service Reference Costs 2015–2016. London, UK. DoH; 2016. Available at: https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016
- Hawton AJ, Green C. Multiple sclerosis: relapses, resource use, and costs. Eur J Health Econ 2016;17:875-84
- Hawton A, Green C. Health utilities for multiple sclerosis. Value Health 2016;19:460-8
- Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
- Acaster S, Perard R, Chauhan D, et al. A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis. BMC Health Serv Res 2013;13:346
- National Institute for Health and Care Excellence. TA312 - Alemtuzumab for treating relapsing-remitting multiple sclerosis. England, UK. NICE; 2014. Available at: https://www nice org uk/guidance/ta312
- National Institute for Health and Care Excellence [Internet]. Daclizumab for treating relapsing–remitting multiple sclerosis. England, UK. NICE; 2017. Available at: https://www.nice.org.uk/guidance/ta441
- Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 2011;10:329-37
- Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801
- Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
- Bell Gorrod H, Latimer N, Damian D, et al. Adjusting for treatment switching in the relapsing-remitting multiple sclerosis clarity trial and the clarity extension study. Value Health 2017;20:A718
- Bell Gorrod H, Latimer N, Damian D, et al. Impact of non-randomised drop-out on treatment switching adjustment in the relapsing-remitting multiple sclerosis clarity trial and the clarity extension study. Value Health 2017;20:A769
- National Institute for Health and Care Excellence [Internet]. TA493 - Cladribine tablets for treating relapsing–remitting multiple sclerosis. England, UK. NICE; 2017. Available at: https://www.nice.org.uk/guidance/ta493
- Merck. Data on File. Summarizing patient preferences for the competitive landscape of relapsing-remitting multiple sclerosis disease modifying treatment options. Feltham, UK. Merck; 2017
- National Institute for Health and Care Excellence [Internet]. TA254 - Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis. England, UK. NICE; 2012. Available at: https://www.nice.org.uk/guidance/ta254
- Wong SL, Aldridge J, Hettle R, et al. Analysis of 6-month confirmed disability progression in RRMS patients treated with subcutaneous interferon beta-1a. Presented at: ACTRIMS Forum 2018; February 1-3, 2018; San Diego, CA. Abstract P047
- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
- Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm 2015;2:e158
- Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12:219-30
- Phillips JT, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care 2015;17:236-43
- Trogdon JG, Ekwueme DU, Chamiec-Case L, et al. Breast cancer in young women: health state utility impacts by race/ethnicity. Am J Prevent Med 2016;50:262-9
- British National Formulary [Internet]. British National Formulary; 2017. London, UK. Available at: https://www.medicinescomplete.com/mc/bnf/64/
- Department of Health and Social Care [Internet]. Drugs and pharmaceutical electronic market information (eMit). London, UK. DoHSC; 2018. Available at: http://www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit